Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: Which role for long-acting risperidone?

21Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

Abstract

This study evaluated adherence to treatment, quality of life and subjective well-being in patients with psychosis treated with long-acting injectable risperidone. Subjects enrolled were part of a larger study where patients were observed in an adherence to treatment program of the University of Rome Tor Vergata. A total of 27 nonadherent patients (21 men, six women; mean age: 36.1 years; range: 23–63 years) were enrolled. Maximum observational period was 30 months. A total of 12 patients were under treatment for 30 months (44.44%) but only nine had a valid 30-month follow up, while the remaining three patients initially treated at our unit continued long-acting risperidone at their local centre. Reductions of monthly mean values of Scale for the Assessment of Positive Symptoms (SAPS) [repeated measures analysis of variance (rm-ANOVA): p < 0.0001] and Scale for Assessment of Negative Symptoms (SANS) (p < 0.0001), increase of monthly mean values of Subjective Well-Being Under Neuroleptic Treatment Scale (SWN) (p < 0.0001) and Schizophrenia Quality of Life Scale (S-QoL) (p < 0.01) were observed. Significant differences with respect to SAPS baseline values from the sixth month, SANS baseline values from the seventh month, SWN baseline values from the eighth month, S-QoL baseline values from the eighteenth month were shown in post hoc tests. Reduction of SAPS mean values was associated with increase of SWN (p < 0.0001) and S-QoL (p < 0.0001) mean values as demonstrated by correlation analysis. The same inverse correlation was found between reduction of SANS mean values and increases of SWN (p < 0.0001) and S-QoL (p = 0.0001) mean values. Long-term treatment with long-acting risperidone may be associated with improvement to adherence to therapy and quality of life. Patients may show improvement in psychopathological symptoms, subjective well-being and quality of life. © 2015, SAGE Publications. All rights reserved.

References Powered by Scopus

Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature

1205Citations
N/AReaders
Get full text

Medication adherence and long-term functional outcomes in the treatment of Schizophrenia in usual care

421Citations
N/AReaders
Get full text

Oral versus depot antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of randomised long-term trials

395Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Second-generation long-acting injectable antipsychotics in schizophrenia: Patient functioning and quality of life

33Citations
N/AReaders
Get full text

Economic burden of schizophrenia in Italy: A probabilistic cost of illness analysis

24Citations
N/AReaders
Get full text

Non-adherence to pharmacological treatment in schizophrenia and schizophrenia spectrum disorders – An updated systematic literature review

21Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Niolu, C., Bianciardi, E., di Lorenzo, G., Marchetta, C., Barone, Y., Sterbini, N., … Siracusano, A. (2015). Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: Which role for long-acting risperidone? Therapeutic Advances in Psychopharmacology, 5(5), 278–288. https://doi.org/10.1177/2045125315596897

Readers' Seniority

Tooltip

Researcher 10

45%

PhD / Post grad / Masters / Doc 9

41%

Professor / Associate Prof. 3

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

43%

Psychology 5

24%

Nursing and Health Professions 4

19%

Pharmacology, Toxicology and Pharmaceut... 3

14%

Save time finding and organizing research with Mendeley

Sign up for free